Back

Panelists discuss the role of ADCs in solid tumor care, explore the ocular adverse events associated with these agents, and discuss best practices for monitoring and managing ocular toxicities in clinical practice.

Integrating Ocular Toxicity Management into Routine Care for Solid Tumor Patients Receiving Treatment with ADCs

Episodes

Specialty:

All

Year:

All

EP. 1: Antibody Drug Conjugates (ADCs) for Treatment of Solid Tumors

ByJacob Sands, MD,Laura Huppert, MD,Thomas J. Herzog, MD,Sarah Sunshine, MD

December 16th 2025

Experts discuss the integration of ocular toxicity management in solid tumor care, focusing on antibody-drug conjugates and their impact on treatment.

EP. 2: Classifying ADC Associated Ocular Toxicities and Evaluating Them in Everyday Practice

ByJacob Sands, MD,Laura Huppert, MD,Thomas J. Herzog, MD,Sarah Sunshine, MD

December 16th 2025

Ocular toxicities from cancer treatments present complexities; understanding symptoms and timely ophthalmology involvement is crucial for effective management.

EP. 3: Strengthening Oncology–Ophthalmology Communication for Management of ADC Associated Ocular Toxicities

ByJacob Sands, MD,Laura Huppert, MD,Thomas J. Herzog, MD,Sarah Sunshine, MD

December 22nd 2025

Experts discuss the integration of ocular toxicity management in solid tumor care, focusing on antibody-drug conjugates and their impact on treatment.

EP. 4: Defining Grade 1 Ocular Toxicities and When to Prioritize Baseline Eye Exams While Using ADCs

ByJacob Sands, MD,Laura Huppert, MD,Thomas J. Herzog, MD,Sarah Sunshine, MD

December 22nd 2025

Ophthalmologists discuss the importance of grading dry eye symptoms and the necessity of eye exams before starting certain treatments.

EP. 5: Managing Ocular Symptoms and Comorbidities with ADC Use: When to Involve Ophthalmologists

ByJacob Sands, MD,Laura Huppert, MD,Thomas J. Herzog, MD,Sarah Sunshine, MD

January 6th 2026

Medical oncologists explore the importance of ophthalmology referrals for ocular toxicities, emphasizing collaboration for optimal patient care.

EP. 6: Ocular Toxicities Across Breast, Lung, and Gynecologic ADCs: Incidence, Management, and Clinical Implications

ByJacob Sands, MD,Laura Huppert, MD,Thomas J. Herzog, MD,Sarah Sunshine, MD

January 6th 2026

Explore the latest insights on antibody-drug conjugates in oncology and their associated ocular toxicities, enhancing patient care and treatment outcomes.

EP. 7: Managing ADC Dose Adjustments to Improve Ocular Toxicities

ByJacob Sands, MD,Laura Huppert, MD,Thomas J. Herzog, MD,Sarah Sunshine, MD

January 13th 2026

Experts discuss the challenges of ocular toxicities in oncology, emphasizing collaboration and the importance of preservative-free eye drops for patient care.

EP. 8: Best Practices for Discussing and Managing Ocular Surface Toxicities When Using ADCs for Solid Tumors

ByJacob Sands, MD,Laura Huppert, MD,Thomas J. Herzog, MD,Sarah Sunshine, MD

January 13th 2026

Experts discuss the challenges of ocular toxicities in oncology, emphasizing collaboration and the importance of preservative-free eye drops for patient care.

EP. 9: Defining the Roles of Ophthalmologists and Optometrists in Managing ADC-Related Ocular Toxicities

ByJacob Sands, MD,Laura Huppert, MD,Thomas J. Herzog, MD,Sarah Sunshine, MD

January 20th 2026

Explore the roles of optometrists and ophthalmologists in managing ocular toxicities, ensuring timely patient care and effective treatment strategies.

EP. 10: Aligning Clinical Trial Findings With Real-World Ocular Toxicity Outcomes with ADCs in Solid Tumors

ByJacob Sands, MD,Laura Huppert, MD,Thomas J. Herzog, MD,Sarah Sunshine, MD

January 20th 2026

Experts discuss the alignment of clinical trial data with real-world experiences in managing ocular toxicities in cancer treatments.

EP. 11: Differentiating Urgent vs. Non-Urgent Ocular AEs in ADC-Treated Patients

ByJacob Sands, MD,Laura Huppert, MD,Thomas J. Herzog, MD,Sarah Sunshine, MD

January 27th 2026

Experts discuss the importance of monitoring ocular toxicities in cancer treatment, emphasizing timely interventions and effective communication between oncologists and ophthalmologists.

EP. 12: Variability in Prophylactic Strategies and Use of Supportive Care Across ADCs

ByJacob Sands, MD,Laura Huppert, MD,Thomas J. Herzog, MD,Sarah Sunshine, MD

January 27th 2026

Explore the differences in supportive care for antibody-drug conjugates and their impact on ocular health in patients.

EP. 13: Multidisciplinary Collaboration for Identifying and Managing ADC-Related Ocular Toxicities

ByJacob Sands, MD,Laura Huppert, MD,Thomas J. Herzog, MD,Sarah Sunshine, MD

February 3rd 2026

Oncology care thrives on teamwork, emphasizing patient education and communication to manage treatment-related ocular toxicities effectively.

Integrating Ocular Toxicity Management into Routine Care for Solid Tumor Patients Receiving Treatment with ADCs

Episodes

EP. 1: Antibody Drug Conjugates (ADCs) for Treatment of Solid Tumors

EP. 2: Classifying ADC Associated Ocular Toxicities and Evaluating Them in Everyday Practice

EP. 3: Strengthening Oncology–Ophthalmology Communication for Management of ADC Associated Ocular Toxicities

EP. 4: Defining Grade 1 Ocular Toxicities and When to Prioritize Baseline Eye Exams While Using ADCs

EP. 5: Managing Ocular Symptoms and Comorbidities with ADC Use: When to Involve Ophthalmologists

EP. 6: Ocular Toxicities Across Breast, Lung, and Gynecologic ADCs: Incidence, Management, and Clinical Implications

EP. 7: Managing ADC Dose Adjustments to Improve Ocular Toxicities

EP. 8: Best Practices for Discussing and Managing Ocular Surface Toxicities When Using ADCs for Solid Tumors

EP. 9: Defining the Roles of Ophthalmologists and Optometrists in Managing ADC-Related Ocular Toxicities

EP. 10: Aligning Clinical Trial Findings With Real-World Ocular Toxicity Outcomes with ADCs in Solid Tumors

EP. 11: Differentiating Urgent vs. Non-Urgent Ocular AEs in ADC-Treated Patients

EP. 12: Variability in Prophylactic Strategies and Use of Supportive Care Across ADCs

EP. 13: Multidisciplinary Collaboration for Identifying and Managing ADC-Related Ocular Toxicities

Trending on OncLive

Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma

ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC

FDA Grants Fast Track Designation to PLN-101095 Plus Pembrolizumab in Solid Tumors

mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC

Harold P. Freeman, MD, Pioneer of Patient Navigation and Cancer Disparities Research, Dies at 93